A Bengaluru-based start-up NIRAMAI Health Analytix has raised about $6 million through funding led by a Japanese venture capital firm called Dream Incubator. It’s a health tech start-up that aims to scale its AI-driven technology across India and expand its employee count in the near future too.
The company has emerged with an AI-derived Thermalytix tech to detect various classes of cancer, most commonly breast cancer. The company is already operating in nine Indian cities for the sole purpose of early detection of breast cancer.
The start-up MIRAMAI is an acronym for Non-Invasive Risk Assessment with Machine Learning and is being led by cofounders — Dr Geetha Manjunath and Nidhi Mathur.
Dr Geetha Manjunath and Nidhi Mathur, the cofounders of the NIRMAI Group.
The company also intends to expand its business in the international market, after tasting success in India, with over 22 centres being efficacious. Many Indian companies like pi Ventures, Ankur Capital, Axilor Ventures, etc., have been investing in the organisation.
What makes the company and its methods for Breast Cancer detection unique, is the fact that the technology used for screening is radiation-free and doesn’t require any incisions. It is also non-touch and privacy-conscious, so no one ever touches you during the entire process of diagnosis. Also, the device sensitivity, as well as the specificity is off the charts.
As technology becomes more suited and accepted by Indian Medical Institutions, the chance of saving innocent lives become exponentially higher by the day.